Apomorphine is believed to treat off episodes associated with PD through stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Parkinsonism
Sublingual Apomorphine Hydrochloride Approved for Off Episodes in Parkinson Disease
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
Deep Brain Stimulation System Gains Expanded Approval for Parkinson Disease Management
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
FDA to Review Resubmitted NDA for Apomorphine Sublingual Film
The FDA has accepted for review the resubmitted New Drug Application (NDA) for apomorphine sublingual film (APL-130277; Sunovion) for the treatment of OFF episodes in patients with Parkinson disease (PD).
Palliative Care in Movement Disorders: Recommendations for Improvement
Parkinsonism syndromes are associated with progressive disability and increased mortality, with symptom burden comparable to that of advanced cancer.
- Loading...
Loading...
Next post in Movement Disorders
Loading... 
Loading...